J&J boasts improved cardio safety with SGLT2 franchise drug Invokana
J&J scored vitally important cardio safety data for its SGLT2 diabetes drug Invokana in a large Phase III outcomes study, which it happily shared with researchers at the annual American Diabetes Association conference in San Diego on Monday afternoon.
The pharma giant $JNJ spelled out a slate of positive risk reductions on three key measures, with a 14% reduction in risk for a composite score on CV mortality as well as nonfatal myocardial infarction and stroke, with each measure contributing to the positive score.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters